Evoke Pharma (NASDAQ:EVOK) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company’s lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. “
Other analysts also recently issued research reports about the company. B. Riley reaffirmed a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a research report on Wednesday, November 15th. HC Wainwright set a $9.00 price target on Evoke Pharma and gave the stock a “buy” rating in a research report on Wednesday, November 29th. FBR & Co reissued a “buy” rating and set a $10.00 price target on shares of Evoke Pharma in a research report on Monday, October 30th. ValuEngine downgraded Evoke Pharma from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Northland Securities reissued a “buy” rating and set a $10.00 price target on shares of Evoke Pharma in a research report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $9.14.
Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.13). During the same quarter last year, the business earned ($0.29) earnings per share. equities analysts anticipate that Evoke Pharma will post -1 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Creative Planning acquired a new position in Evoke Pharma during the fourth quarter worth approximately $226,000. Sphera Funds Management LTD. increased its position in Evoke Pharma by 14.2% during the third quarter. Sphera Funds Management LTD. now owns 571,022 shares of the specialty pharmaceutical company’s stock worth $1,907,000 after buying an additional 71,022 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Evoke Pharma by 15.1% during the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after buying an additional 68,544 shares during the last quarter. 14.29% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/06/evoke-pharma-evok-raised-to-hold-at-zacks-investment-research.html.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.